{"id":"growth-hormone-treatment-and-puberty","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Growth hormone (somatotropin) binds to growth hormone receptors on target tissues, activating JAK-STAT and MAPK signaling cascades that promote protein synthesis, lipolysis, and insulin resistance. During puberty, GH works synergistically with sex steroids to accelerate linear growth velocity, increase lean body mass, and modulate metabolic parameters. The treatment is used to optimize growth outcomes in children with growth hormone deficiency or growth disorders during the pubertal transition.","oneSentence":"Growth hormone treatment stimulates linear growth and metabolic effects during puberty by binding to growth hormone receptors and activating downstream signaling pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:49.893Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children during puberty"},{"name":"Growth disorders in pediatric patients undergoing pubertal development"}]},"trialDetails":[{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT00840944","phase":"PHASE4","title":"A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height","status":"UNKNOWN","sponsor":"Belgian Study Group for Pediatric Endocrinology","startDate":"2008-01","conditions":"Idiopathic Short Stature","enrollment":44},{"nctId":"NCT00206375","phase":"PHASE4","title":"Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2003-05","conditions":"Hypothyroidism","enrollment":16},{"nctId":"NCT02199587","phase":"NA","title":"The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test","status":"COMPLETED","sponsor":"Meir Medical Center","startDate":"2014-12-17","conditions":"Precocious Puberty, Growth Hormone Tests","enrollment":58},{"nctId":"NCT01797718","phase":"PHASE2, PHASE3","title":"Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-10","conditions":"Constitutional Delay of Growth and Puberty","enrollment":35},{"nctId":"NCT01518062","phase":"PHASE4","title":"Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1989-11","conditions":"Genetic Disorder, Turner Syndrome","enrollment":65},{"nctId":"NCT01400698","phase":"PHASE3","title":"Saizen in Intra-uterine Growth Retardation","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"1998-11","conditions":"Children Born With Serious Intra-uterine Growth Retardation","enrollment":91},{"nctId":"NCT00133354","phase":"PHASE2, PHASE3","title":"Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2001-11","conditions":"Hypopituitarism","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humatrope"],"phase":"marketed","status":"active","brandName":"Growth hormone treatment and puberty","genericName":"Growth hormone treatment and puberty","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Growth hormone treatment stimulates linear growth and metabolic effects during puberty by binding to growth hormone receptors and activating downstream signaling pathways. Used for Growth hormone deficiency in children during puberty, Growth disorders in pediatric patients undergoing pubertal development.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}